StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) stock

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38+0.00 (0.00%)

Close on Nov 18, 2026Market cap $192.56MP/E –Yield –

Inhibikase Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Inhibikase Therapeutics's revenue for the twelve months ending Sep 30, 2025 was $0, down 100.0% year over year. For fiscal 2024 it was $0, down 100.0% from the year before. The highest annual figure on record is $3.10M in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2024Dec 31, 2024$0-100.0%
FY2023Dec 31, 2023$260.50K+111.0%
FY2022Dec 31, 2022$123.44K-96.0%
FY2021Dec 31, 2021$3.10M+343.9%
FY2020Dec 31, 2020$698.47K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$0–
Q1 FY2026Mar 31, 2026$0–
Q3 FY2025Sep 30, 2025$0–
Q2 FY2025Jun 30, 2025$0–
Q1 FY2025Mar 31, 2025$0–
Q4 FY2024Dec 31, 2024$0-100.0%
Q3 FY2024Sep 30, 2024$0-100.0%
Q2 FY2024Jun 30, 2024$0-100.0%
Q1 FY2024Mar 31, 2024$0-100.0%
Q4 FY2023Dec 31, 2023$1-100.0%
Q3 FY2023Sep 30, 2023$79.57K+991.3%
Q2 FY2023Jun 30, 2023$116.41K+1676.7%
Q1 FY2023Mar 31, 2023$64.52K+40.2%
Q4 FY2022Dec 31, 2022$63.57K-95.3%
Q3 FY2022Sep 30, 2022$7.29K-99.5%
Q2 FY2022Jun 30, 2022$6.55K-96.2%
Q1 FY2022Mar 31, 2022$46.03K+22.2%
Q2 FY2021Jun 30, 2021$1.36M+520.7%
Q1 FY2021Mar 31, 2021$1.41M+419.7%
Q4 FY2020Dec 31, 2020$170.42K–
Q3 FY2020Sep 30, 2020$37.68K–
Q2 FY2020Jun 30, 2020$219.59K–
Q1 FY2020Mar 31, 2020$270.79K–

More Inhibikase Therapeutics figures

See a number that looks wrong?